Insulet to Announce Second Quarter 2018 Financial Results on August 2, 2018

BILLERICA, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global
leader in tubeless
insulin pump
technology with its Omnipod® Insulin
Management System, today announced plans to release its financial
results for the second quarter of 2018 on August 2, 2018 after the close
of the financial markets. In connection with the release, management
will host a conference call that day at 4:30 p.m. (Eastern Time).

The link to the live call will be available on the Investor Relations
section of the Company’s website at http://investors.insulet.com,
“Events and Presentations”, and will be archived for future replay. You
may also access the live call by dialing (844) 831-3022 for domestic
callers or (315) 625-6887 for international callers, passcode is 3342069.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is
an innovative medical device company dedicated to making the lives of
people with diabetes and other conditions easier through the use of its
Omnipod product platform. The Omnipod Insulin Management System provides
a unique alternative to traditional insulin delivery methods. With its
simple, wearable design, the disposable Pod provides up to three days of
non-stop insulin delivery, without the need to see or handle a needle.
Insulet also leverages the unique design of its Pod, by tailoring its
Omnipod technology platform for the delivery of non-insulin subcutaneous
drugs across multiple therapeutic areas. Founded in 2000, more than
140,000 users across the globe rely on Insulet’s Omnipod Insulin
Management System to bring simplicity and freedom to their lives.

On July 1, 2018, Insulet assumed direct distribution of its Omnipod
Insulin Management System in Europe, including sales, marketing,
training and customer support activities. This allows Insulet to be
closer to the diabetes community and identify opportunities to support
European customer needs over the long-term, as it does in the United
States and Canada.

For more information, please visit: www.insulet.com
and www.myomnipod.com.

Contacts

Insulet Corporation
Investor Relations and Media Contact:
Deborah
R. Gordon, 978-600-7717
Vice President, Investor Relations and
Corporate Communications
dgordon@insulet.com